Evidence map›Paper›PMID 39917931›Full record

ArticleCurrent medicinal chemistry2026

Inhibition of Shiga Toxin 2 for

Ashiq Ali, Isra Noor, Maleeha Shaukat, Warda Waheed, Kaynaat Akbar, Ziyi Ji, Zhongjing Su

Abstract read
PubMed Publisher
In one paragraph

Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Potato (Molecules (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ashiq AliDepartment of Histology and Embryology, Shantou University Medical College, Shantou, China.
Isra NoorInstitute of Microbiology, University of Agriculture Faisalabad, Faisalabad, Pakistan.
Maleeha ShaukatInstitute of Microbiology, University of Agriculture Faisalabad, Faisalabad, Pakistan.
Warda WaheedInstitute of Microbiology, University of Agriculture Faisalabad, Faisalabad, Pakistan.
Kaynaat AkbarDepartment of Zoology, Wildlife and Fisheries, University of Agriculture Faisalabad, Faisalabad, Pakistan.
Ziyi JiDepartment of Histology and Embryology, Shantou University Medical College, Shantou, China.
Zhongjing SuDepartment of Histology and Embryology, Shantou University Medical College, Shantou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

INTRODUCTION/

objectivesEscherichia coli strains are known to cause various gastrointestinal disorders, with Shiga toxin 2, a potent cytotoxin, being a key virulence factor contributing to disease severity. Targeting Shiga toxin 2 presents a promising approach for therapeutic intervention in controlling E. coli O157 infections. This study aims to explore natural and synthetic inhibitors as potential therapeutic agents against Shiga toxin 2 through in-silico molecular docking and drug-likeness predictions.

methodsAn in-silico molecular docking study was conducted using AutoDock Vina and Chimera to assess the binding affinity of various natural and synthetic inhibitors against Shiga toxin 2. The selected inhibitors were evaluated for their drug-likeness based on adsorption, distribution, metabolism, and excretion (ADME) properties, applying Lipinski's rule of five and the Boiled-Egg technique to predict their suitability as potential drugs in biological systems.

resultsDuring the screening process, luteolin, a natural flavonoid, exhibited the highest binding affinity to Shiga toxin 2, with a notable negative binding energy of -8.7 kcal/- mol, indicating strong interaction potential.

conclusionThe findings suggest that luteolin holds promise as a lead molecule for further development as a therapeutic agent against E. coli infections, warranting additional studies to validate its efficacy and safety.

Indexed as

Anti-Bacterial AgentsBiological ProductsEscherichia coli O157Shiga Toxin 2Computer SimulationMolecular Docking SimulationAnti-Bacterial AgentsBiological ProductsShiga Toxin 2E. coli infections.hemolytic uremic syndrome (HUS)inhibitorsLipinski’s rulesMolecular dockingShiga toxin

Identifiers

PMID39917931

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.